Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population

作者：Federica Lo Prinzi, Francesca Salani, Silvia Camera, Mario Domenico Rizzato, Anna Lena Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters, Tiziana Pressiani, Jessica Lucchetti, Jin Won Kim, Oluseyi Abidoye, Ilario Giovanni Rapposelli, Chiara Gallio, Stefano Tamberi, Fabian Finkelmeier, Guido Giordano, Pircher Chiara, Hong Jae Chon, Chiara Braconi, Aitzaz Qaisar, Alessandro Pastorino, Florian Castet, Emiliano Tamburini, Changhoon Yoo, Alessandro Parisi, Anna Diana, Mario Scartozzi, Gerald W. Prager, Antonio Avallone, Marta Schirripa, Il Hwan Kim, Lukas Perkhofer, Ester Oneda, Monica Verrico, Nuno Couto, Jorge Adeva, Stephen Lam Chan, Gian Paolo Spinelli, Nicola Personeni, Ingrid Garajová, Maria Grazia Rodriquenz, Silvana Leo, Cecilia Melo Alvim, Ricardo Roque, Mariam Grazia Polito, Emanuela Di Giacomo, Giovanni Farinea, L. Bartalini, Giada Grelli, Antonio De Rosa, Daniele Lavacchi, Masafumi Ikeda, Jeroen Dekervel, Monica Niger, Rita Balsano, Giuseppe Tonini, Min-Su Kang, Giulia Tesini, Alessandra Boccaccino, Vera Himmelsbach, Matteo Landriscina, Selma Ahcene Djaballah, Tanios Bekaii‐Saab, Lorenzo Fornaro, Gianluca Masi, Arndt Vogel, Sara Lonardi, Margherita Rimini, Lorenza Rimassa, Andrea Casadei‐Gardini · 发表于：International Journal of Cancer · 年份：2025 · DOI：10.1002/ijc.70009 · 被引用次数：5 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Neuroendocrine Tumor Research Advances、Peptidase Inhibition and Analysis

In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real-world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were available for 493 patients. After a median follow-up of 8.8 months (95% CI: 7.8-9.8), patients who did not take steroids (prednisone >10 mg/day or equivalent) or nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, before the start of CGD, had longer OS and PFS in univariate analysis. The multivariate analysis confirmed longer OS for patients who did not take steroids. Patients who did not take steroids had an OS of 14.8 months (95% CI: 13.1-29.1) versus 5.0 months (95% CI: 2.14-11.32) of patients who took prednisone >10 mg/day or equivalent. No differences were reported in terms of overall response rate (ORR), disease control rate (DCR) (p = 1.0 and p = .16, respectively), and safety pro...